Ranexa Advisory Cmte. Review Cancelled; User Fee Date May Be Extended

CV Therapeutics sees a Ranexa action letter or a user fee date extension as FDA's next possible steps following the cancellation of the angina agent's September review by FDA's Cardiovascular & Renal Drugs Advisory Committee